Mechanism of Action
Tyndallised Bifidobacterium longum acts exclusively through its preserved cellular structures, without intestinal colonisation. Tyndallisation is a controlled heat treatment that inactivates bacterial cells while preserving intact their surface components: peptidoglycan, a constituent of the bacterial cell wall, and lipoteichoic acid (LTA). These structural molecules are recognised by TLR2 receptors (Toll-Like Receptor 2) expressed on epithelial and immune cells of the intestinal mucosa. This recognition triggers intracellular signalling that modulates the local immune response, reinforces protective mucus production, and stabilises tight junctions between epithelial cells. B. longum also influences the gut-brain axis through tryptophan metabolism and intestinal serotonergic signalling, which distinguishes this species from other bifidobacteria. Unlike a live probiotic, tyndallised cells do not produce active metabolites (short-chain fatty acids, lactate) since their metabolism is inactivated. Their biological activity is entirely mediated by these preserved cellular structures, which maintain their capacity to interact with immune receptors even after thermal inactivation.
Key Benefits
- Strong
A double-blind randomised controlled trial (n=200, 12 weeks) showed that the tyndallised form HT-ES1 of B. longum CECT 7347 significantly reduces the IBS Symptom Severity Score (IBS-SSS) versus placebo in adults with diarrhea-predominant IBS.
- Moderate
The tyndallised form of B. longum CECT 7347 preserves the capacity to modulate the innate immune response, reduce intestinal inflammation markers, and protect the epithelial barrier, as documented in cellular and in vivo models.
- Emerging
Multiple centenarian and supercentenarian cohort studies from different world regions identify B. longum as one of the most consistent microbial signatures of longevity, with significantly higher abundance than in younger adults.
- Emerging
A pilot trial in healthy adults (n=60, 8 weeks) showed an increase in butyrate-producing bacteria in the fecal microbiota and a reduction in total and non-HDL cholesterol after HT-ES1 supplementation.
- Emerging
Preliminary data suggest that B. longum influences the gut-brain axis through tryptophan metabolism and serotonergic signalling, with potential implications for well-being and sleep quality.
Dosage & Forms
The dose in this formula is 50 mg per day, corresponding to 5 billion equivalent cells (concentration: 100 billion per gram). This dosage exceeds the clinical reference dose of 2.5 billion cells used in the main randomised controlled trial on the tyndallised form HT-ES1, providing an additional comfort margin. It is important to note that the dosage of a tyndallised postbiotic should not be read as that of a live probiotic. Tyndallised cells do not need to "colonise" the intestine to act: their mechanism of action relies on the direct interaction of their cellular structures with immune receptors in the mucosa. Consistency of intake is more determinant than the amount ingested at any given time. Daily intake, ideally at the same time of day, optimises the continuous stimulation of mucosal TLR2 receptors.
In the Singular Formula
Inclusion rationale
Bifidobacterium longum is the bifidobacterium most closely associated with human longevity. Among bacterial genera, bifidobacteria colonise the intestine from birth and their proportion progressively declines with age — a phenomenon correlated with the decline of mucosal immunity and increased low-grade inflammation. Analyses spanning multiple independent centenarian cohorts from different world regions consistently identify B. longum among the most consistent microbial signatures in individuals who have surpassed 100 years. A recent systematic review (Food Science and Biotechnology, 2024) designates B. longum as the flagship strain of this association and analyses potential mechanisms: mucosal immunomodulation, gut-brain axis, inflammaging reduction. The tyndallised (postbiotic) form is not a degraded probiotic: tyndallisation preserves the active bacterial structures — peptidoglycan and lipoteichoic acid — that stimulate immune receptors in the mucosa without colonisation. A double-blind randomised controlled trial (n=200, 12 weeks) demonstrated significant efficacy of the tyndallised HT-ES1 form on digestive symptoms versus placebo. A pilot trial in healthy adults confirmed impact on microbiota composition, with an increase in butyrate-producing bacteria and a reduction in non-HDL cholesterol. In the formula, tyndallised B. longum acts synergistically with GOS (prebiotic fibres that selectively nourish endogenous bifidobacteria), Bacillus subtilis with complementary mechanisms, and Akkermansia muciniphila, specialist in mucosal barrier reinforcement.
Selected form
Bifidobacterium longum in tyndallised form (postbiotic), concentrated at 100 billion equivalent cells per gram. Tyndallisation is a controlled heat treatment that inactivates bacterial cells while fully preserving their structural components — cell wall, peptidoglycan, lipoteichoic acid. These components retain their capacity to interact with immune receptors in the intestinal mucosa. Unlike a live probiotic that requires refrigeration to maintain viability, this postbiotic is stable at room temperature and requires no cold chain. This superior stability ensures consistent biological activity throughout its shelf life. Quality: vegan, non-GMO.
Formula dosage
0 to 100 mg.
Synergies in the formula
Safety & Precautions
Bifidobacterium longum has a long history of safe use in human nutrition and supplementation. The tyndallised form presents a superior safety profile compared to the live form: since the cells are inactivated, any risk of unwanted bacterial proliferation is eliminated. No clinically significant drug interactions are documented. Unlike live probiotics, concurrent use with antibiotics does not affect the postbiotic's activity, as its cells are already inactivated. Supplementation is inadvisable in individuals with severe immunodeficiency (heavy immunosuppressive therapy, recent organ transplant), as a general precaution applicable to all ingredients of microbial origin — although this risk is significantly lower than with live forms. Pregnant or breastfeeding women are advised to consult their doctor before supplementation.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Srivastava S et al. | 2024 | Randomised Controlled Trial | Gut Microbes | View on PubMed |
A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome Double-blind randomised controlled trial (n=200, 12 weeks) comparing the live form ES1 and the tyndallised form HT-ES1 of B. longum CECT 7347 versus placebo in adults with diarrhea-predominant IBS. The HT-ES1 form showed a significant reduction in IBS-SSS score versus placebo. | ||||
| Naghibi M et al. | 2024 | Randomised Controlled Trial | Nutrients | View on PubMed |
Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study Double-blind randomised pilot trial (n=60, 8 weeks) in healthy adults with mild-to-moderate digestive symptoms. HT-ES1 postbiotic supplementation increased butyrate-producing bacteria and significantly reduced total and non-HDL cholesterol versus placebo. | ||||
| Ku S et al. | 2024 | Systematic Review | Food Science and Biotechnology | View on PubMed |
The role of Bifidobacterium in longevity and the future of probiotics Systematic review exploring the link between bifidobacteria and human longevity. B. longum is identified as the strain most consistently associated with centenarians. The review analyses potential mechanisms (immunomodulation, gut-brain axis, anti-inflammaging) and therapeutic perspectives. | ||||
| Chen S et al. | 2024 | Cohort Study | Gut Microbes | View on PubMed |
Consistent signatures in the human gut microbiome of longevous populations Analysis of eight cohorts of longevous populations from different world regions. B. longum is among the most consistent microbial signatures in centenarians and supercentenarians, with significantly higher abundance than in younger adults from the same region. | ||||
| Martorell P et al. | 2021 | Preclinical Study | Antioxidants | View on PubMed |
Heat-Treated Bifidobacterium longum CECT-7347: A Whole-Cell Postbiotic with Antioxidant, Anti-Inflammatory, and Gut-Barrier Protection Properties Preclinical study (Caenorhabditis elegans + HT-29 cell cultures) demonstrating that the tyndallised form of B. longum CECT-7347 retains its antioxidant, anti-inflammatory, and intestinal barrier-protective properties after thermal inactivation, through activation of innate immunity. | ||||